Key Insights

Highlights

Treatment Research

1 treatments under study, led by Temsirolimuspld

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00982631Phase 1UnknownPrimary

A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Temsirolimuspld1

Active Sponsors

  • Radboud University Medical Center1

Top Investigators

Related Conditions

  • Endometrial Cancer1
  • Ovarian Cancer1

Activity Timeline